News

According to the World Health Organisation (WHO), approximately 1.5 million people die each year from tuberculosis (TB), a disease of the lungs caused by Mycobacterium tuberculosis. People with a

The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available

This is what ideal medicine would look like: Doctors could specifically alter molecular processes in diseased cells in the body and thus causally cure patients. This is the goal of the German Centers

The human immunodeficiency virus HIV-1 is able to infect various tissues in humans. Once inside the cells, the virus integrates its genome into the cellular genome and establishes persistent

A long-term study by the Research Center Borstel, Leibniz Lung Center was able to show that the therapeutic success of patients with multidrug-resistant tuberculosis is much higher than previously

How can the results of molecular resistance tests be used to optimize drug therapy for tuberculosis? An international panel of experts has updated a consensus document outlining how to interpret

In October 2022, Dr Klaus Schwamborn took over as Head of Vaccine Development in the Translational Project Management Office (TPMO) at DZIF. The TPMO supports product development, from active

Professor Christoph Lange, Medical Director of the Research Center Borstel, Leibniz Lung Center, and scientist at the German Center for Infection Research (DZIF) has now been elected by the members of

DZIF scientist and epidemiologist Prof. Gérard Krause will join the World Health Organisation (WHO) on 1 March 2023, where he will become the director of a newly established Department for

The development of antibiotic resistance is increasingly complicating the treatment of tuberculosis. Patients suffering from multidrug-resistant tuberculosis (MDR-TB) are particularly hard hit. In